Research
Hormonal
SGLT2 inhibitors reduce the risk of heart failure, cardiovascular events, and renal progression in patients with type 2 diabetes, independent of glycemic control.
If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys, not just your blood sugar.
StrongSupportsVERY_HIGH confidence
Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events.
Why this rating
Supported by multiple large, landmark randomized controlled trials (EMPA-REG, CANVAS, DAPA-HF, CREDENCE, etc.).
Source
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong et al. · The Kaohsiung Journal of Medical Sciences · 2024
narrative_reviewCited 49×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →